[Skip to Content]
[Skip to Content Landing]
Research Letter
January 2018

Association of Treatment at High-Volume Facilities With Survival in Patients Receiving Chemoradiotherapy for Nasopharyngeal Cancer

Author Affiliations
  • 1Department of Radiation Oncology, University of Nebraska Medical Center, Omaha
  • 2Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston
  • 3Department of Radiation Oncology, University of Maryland Medical Center, Baltimore
  • 4Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri
JAMA Otolaryngol Head Neck Surg. 2018;144(1):86-89. doi:10.1001/jamaoto.2017.1874

Similar to other head and neck cancers, successful delivery of radiation therapy (RT) in nasopharyngeal cancer (NPC) is challenging. Reasons include technical aspects, such as treatment planning (especially in the era of intensity-modulated RT and simultaneous integrated boosting), physician experience in target delineation (eg, knowing routes of subclinical nodal spread), available technologies (eg, image-guided RT), coordination of multimodality therapy, and treatment of acute and late toxic effects.

First Page Preview View Large
First page PDF preview
First page PDF preview